To	O	PART	O
address	O	VERB	O
this	O	DET	O
secondary	O	ADJ	O
aim	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
main	O	ADJ	O
parameters	O	NOUN	B
are	O	AUX	O
observational	O	ADJ	B
and	O	CCONJ	O
questionnaire	O	NOUN	B
measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
parental	I-OUT	ADJ	B
availability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
parent-child	I-OUT	ADJ	B
relationship	I-OUT	NOUN	B
variables	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
children	I-OUT	NOUN	B
's	I-OUT	PART	O
adjustment	I-OUT	NOUN	B
problems	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
children	I-OUT	NOUN	B
's	I-OUT	PART	I
responses	I-OUT	NOUN	B
to	O	PART	O
interparental	O	ADJ	B
violence	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
prospective	O	ADJ	B
cohort	O	NOUN	I
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
characteristics	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
surgery	I-P	NOUN	B
for	I-P	ADP	O
acute	I-P	ADJ	B
hip	I-P	NOUN	I
fracture	I-P	NOUN	I
.	I-P	PUNCT	O


Troponin	B-I	NOUN	B
T	I-I	NOUN	I
(	I-I	PUNCT	O
TnT	I-I	NOUN	B
)	I-I	PUNCT	O
measurements	I-I	NOUN	B
and	O	CCONJ	O
electrocardiographic	B-I	ADJ	B
(	I-I	PUNCT	I
ECG	I-I	PROPN	O
)	I-I	PUNCT	O
recordings	I-I	NOUN	B
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
before	O	ADP	O
operation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
2nd	O	ADJ	O
postoperative	O	ADJ	B
days	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


How	O	SCONJ	O
to	O	PART	O
establish	O	VERB	O
equivalence	O	NOUN	B
when	O	SCONJ	O
data	O	NOUN	B
are	O	AUX	O
censored	O	VERB	B
:	O	PUNCT	O
a	O	DET	O
randomized	B-P	ADJ	B
trial	I-P	NOUN	I
of	I-P	ADP	O
treatments	I-P	NOUN	B
for	I-P	ADP	O
B	I-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
cancer	O	NOUN	B
research	O	NOUN	I
we	O	PRON	O
are	O	AUX	O
more	O	ADV	O
often	O	ADV	O
concerned	O	VERB	O
with	O	ADP	O
survival	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


An	O	DET	O
equivalence	O	ADJ	O
trial	O	NOUN	O
of	O	ADP	O
maintenance	B-I	NOUN	B
therapy	I-I	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
B	I-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
serves	O	VERB	O
as	O	ADP	O
an	O	DET	O
illustration	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
four	B-I	NUM	O
randomised	I-I	ADJ	B
treatment	I-I	NOUN	I
phases	I-I	NOUN	I
,	O	PUNCT	O
each	O	DET	O
of	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
duration	O	NOUN	B
.	O	PUNCT	O


Clinic	B-OUT	ADJ	B
BP	I-OUT	NOUN	B
was	O	AUX	O
measured	O	VERB	O
weekly	O	ADJ	B
with	O	ADP	O
the	O	DET	O
mean	O	ADJ	B
values	O	NOUN	I
of	O	ADP	O
weeks	O	NOUN	B
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
of	O	ADP	O
each	O	DET	O
phase	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
analysis	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	O
with	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
phase	O	NOUN	O
,	O	PUNCT	O
end	O	NOUN	O
of	O	ADP	O
phase	O	NOUN	B
clinic	B-OUT	NOUN	I
BP	I-OUT	NOUN	B
was	O	AUX	O
unchanged	O	ADJ	B
by	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
progestogen	O	NOUN	B
treatments	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
end	O	NOUN	O
point	O	NOUN	O
,	O	PUNCT	O
reductions	B-OUT	NOUN	B
in	I-OUT	ADP	O
ADHD	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
depressive	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anxiety	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
were	O	AUX	O
marked	O	VERB	O
for	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.001	O	NUM	O
for	O	ADP	O
the	O	DET	O
relevant	O	ADJ	O
scale	O	NOUN	O
in	O	ADP	O
each	O	DET	O
symptom	O	NOUN	B
cluster	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Some	O	DET	O
differences	B-OUT	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
for	O	ADP	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
were	O	AUX	O
significant	B-OUT	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
magnitudes	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
small	B-OUT	ADJ	B
and	O	CCONJ	O
likely	O	ADJ	O
of	O	ADP	O
limited	O	ADJ	O
clinical	O	ADJ	B
importance	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
coronary	B-I	ADJ	B
arteriography	I-I	NOUN	I
was	O	AUX	O
done	O	VERB	O
on	O	ADP	O
study	O	NOUN	B
entry	O	NOUN	I
.	O	PUNCT	O


Individual	O	ADJ	B
groups	O	NOUN	O
analysis	O	NOUN	O
showed	O	VERB	O
significative	O	ADJ	O
reductions	B-OUT	NOUN	B
of	O	ADP	O
SAP	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
DAP	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
HR	I-OUT	NOUN	B
in	O	ADP	O
propranolol	B-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
two	B-P	NUM	O
treatment	I-P	NOUN	B
groups	I-P	NOUN	I
were	I-P	AUX	O
closely	I-P	ADV	O
matched	I-P	VERB	B
in	I-P	ADP	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
sex	I-P	NOUN	B
,	I-P	PUNCT	O
per	I-P	ADP	O
cent	I-P	NOUN	O
of	I-P	ADP	O
BSA	I-P	NOUN	B
burned	I-P	VERB	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
in	I-P	ADP	O
burn	I-P	NOUN	B
severity	I-P	NOUN	B
and	I-P	CCONJ	O
locations	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
MVPF	B-I	PROPN	B
group	O	NOUN	B
demonstrated	O	VERB	O
a	O	DET	O
39.0	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
after	O	ADP	O
application	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dressing	O	NOUN	B
over	O	ADP	O
the	O	DET	O
silver	B-I	ADJ	B
sulphadiazine	I-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	B-OUT	ADJ	B
infection	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	ADP	O
healing	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
discrimination	O	NOUN	B
learning	O	NOUN	I
paradigm	O	NOUN	B
,	O	PUNCT	O
children	O	NOUN	B
receiving	O	VERB	O
haloperidol	B-I	NOUN	B
learned	I-OUT	VERB	B
the	I-OUT	DET	O
discrimination	I-OUT	NOUN	B
while	O	SCONJ	O
those	O	DET	O
on	O	ADP	O
placebo	B-I	NOUN	B
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


Discrimination	O	NOUN	B
attained	O	VERB	O
on	O	ADP	O
haloperidol	B-I	NOUN	B
was	O	AUX	O
retained	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
children	O	NOUN	B
were	O	AUX	O
switched	O	VERB	O
to	O	PART	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


METHODS	O	NOUN	O
A	O	DET	O
series	O	NOUN	B
of	O	ADP	O
134	B-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
at	I-P	ADP	O
7	I-P	NUM	O
hospital	I-P	NOUN	B
centers	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	O	NOUN	B
completed	O	VERB	O
a	O	DET	O
questionnaire	B-I	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
symptoms	O	NOUN	B
,	O	PUNCT	O
function	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
overall	O	ADJ	B
satisfaction	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
clear	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
morphine	B-OUT	NOUN	B
requirement	I-OUT	NOUN	B
became	O	VERB	O
evident	O	ADJ	O
after	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.010	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
differences	B-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
resolution	B-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
over	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	B-OUT	ADJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
complications	I-OUT	NOUN	B
was	O	AUX	O
the	O	DET	O
same	O	ADJ	O
,	O	PUNCT	O
specifically	O	ADV	O
fecaloma	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
MM	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
external	B-OUT	ADJ	B
hemorrhoidal	I-OUT	ADJ	B
thrombosis	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.006	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
SH	B-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
patient	O	NOUN	B
needed	O	VERB	O
a	O	DET	O
second	B-OUT	ADJ	O
procedure	I-OUT	NOUN	B
for	O	ADP	O
recurrence	O	NOUN	B
within	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
partial	B-OUT	ADJ	B
residual	I-OUT	ADJ	O
prolapse	I-OUT	NOUN	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
4	O	NUM	O
SH	B-I	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
7.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
versus	O	CCONJ	O
1	O	NUM	O
MM	B-I	NOUN	B
patient	O	NOUN	B
(	O	PUNCT	O
1.8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.194	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Stapled	B-I	PROPN	B
hemorrhoidopexy	I-I	NOUN	I
causes	O	VERB	O
significantly	O	ADV	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Like	O	INTJ	O
with	O	ADP	O
conventional	O	ADJ	B
surgery	B-I	NOUN	I
,	O	PUNCT	O
anorectal	B-OUT	ADJ	B
dysfunction	I-OUT	NOUN	I
can	O	AUX	O
occur	O	VERB	O
after	O	ADP	O
stapled	B-I	ADJ	B
hemorrhoidopexy	I-I	NOUN	I
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Hemorroidopexy	B-I	PROPN	B
is	O	AUX	O
applicable	O	ADJ	O
for	O	ADP	O
treating	O	VERB	B
reducible	O	ADJ	B
hemorrhoidal	O	ADJ	I
prolapse	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
social	O	ADJ	B
behaviors	O	NOUN	I
of	O	ADP	O
4-	B-P	NUM	O
to	I-P	PART	O
12-year-old	I-P	ADJ	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
;	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
24	I-P	NUM	O
)	I-P	PUNCT	O
during	O	ADP	O
three	O	NUM	O
tradic	O	ADJ	B
interactions	O	NOUN	B
with	O	ADP	O
an	B-I	DET	O
adult	I-I	ADJ	B
confederate	I-I	NOUN	B
and	I-I	CCONJ	O
an	I-I	DET	O
interaction	I-I	NOUN	B
partner	I-I	NOUN	O
,	O	PUNCT	O
where	O	SCONJ	O
the	O	DET	O
interaction	O	NOUN	B
partner	O	NOUN	O
varied	O	VERB	O
randomly	O	ADV	O
among	O	ADP	O
(	B-I	PUNCT	O
1	I-I	X	O
)	I-I	PUNCT	O
another	I-I	DET	O
adult	I-I	ADJ	B
human	I-I	ADJ	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
a	I-I	DET	O
touchscreen	I-I	NOUN	B
computer	I-I	NOUN	I
game	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
(	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
a	I-I	DET	O
social	I-I	ADJ	B
dinosaur	I-I	NOUN	I
robot	I-I	NOUN	I
.	O	PUNCT	O


Tumor	B-OUT	NOUN	B
budding	I-OUT	NOUN	I
is	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
in	O	ADP	O
AJCC/UICC	B-P	NOUN	B
stage	I-P	NOUN	I
II	I-P	NUM	I
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


For	O	ADP	O
multivariable	B-I	ADJ	B
analysis	I-I	NOUN	I
,	O	PUNCT	O
Cox	O	PROPN	B
's	O	PART	I
proportional	O	ADJ	B
hazards	O	NOUN	I
regression	O	NOUN	I
models	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
verify	O	VERB	O
non-inferiority	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
pregnancy	O	NOUN	I
rate	O	NOUN	O
of	O	ADP	O
Early	B-I	ADJ	B
hCG	I-I	NOUN	B
administration	I-I	NOUN	B
(	O	PUNCT	O
leading	O	VERB	O
follicle	O	NOUN	B
sizes	O	NOUN	B
within	O	ADP	O
16.0-16.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
diameter	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
Late	B-I	ADJ	B
hCG	I-I	NOUN	I
administration	I-I	NOUN	I
(	O	PUNCT	O
leading	O	VERB	O
follicle	O	NOUN	B
sizes	O	NOUN	B
within	O	ADP	O
18.0-18.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
diameter	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	B-I	SCONJ	O
hCG	I-I	NOUN	B
administered	O	VERB	B
when	O	SCONJ	O
the	O	DET	O
largest	O	ADJ	O
follicle	O	NOUN	B
size	O	NOUN	B
reaches	O	VERB	O
16.0-16.9	O	NUM	O
mm	O	NOUN	O
leads	O	VERB	O
to	O	PART	O
similar	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
ongoing	O	ADJ	O
pregnancy	O	NOUN	B
rates	O	NOUN	I
as	O	ADP	O
when	O	SCONJ	O
it	O	PRON	O
reaches	O	VERB	O
18.0-18.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
IUI	O	NOUN	B
cycles	O	NOUN	B
.	O	PUNCT	O


Managing	O	VERB	O
repetitive	O	ADJ	B
behaviours	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
:	I-P	PUNCT	O
pilot	O	NOUN	B
randomised	O	VERB	I
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
parent	B-P	NOUN	B
group	O	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
response	O	NOUN	B
to	O	PART	O
improved	O	VERB	B
blood	O	NOUN	B
folate	O	NOUN	I
concentrations	O	NOUN	I
,	O	PUNCT	O
many	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
professionals	O	NOUN	I
are	O	AUX	O
asking	O	VERB	O
whether	O	SCONJ	O
a	O	DET	O
folic	B-I	ADJ	B
acid	I-I	NOUN	I
supplement	I-I	NOUN	I
is	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
NTD	O	NOUN	B
prevention	O	NOUN	B
among	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
high	I-P	ADJ	B
blood	I-P	NOUN	O
folate	I-P	NOUN	O
values	I-P	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
how	O	SCONJ	O
reliably	O	ADV	O
high	O	ADJ	O
RBC	O	NOUN	B
folate	O	NOUN	B
concentrations	O	NOUN	I
predict	O	VERB	O
folate	O	NOUN	B
intakes	O	NOUN	B
shown	O	VERB	O
in	O	ADP	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
to	O	PART	O
be	O	AUX	O
protective	O	ADJ	O
against	O	ADP	O
NTDs	O	NOUN	B
.	O	PUNCT	O


Only	O	ADV	O
modest	O	ADJ	O
associations	O	NOUN	B
existed	O	VERB	O
between	O	ADP	O
total	B-OUT	ADJ	O
folate	I-OUT	NOUN	B
intakes	I-OUT	NOUN	O
and	O	CCONJ	O
plasma	B-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.46	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
RBC	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.36	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
folate	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
at	O	ADP	O
16-wk	O	ADJ	O
postpartum	O	NOUN	B
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
RBC	I-OUT	NOUN	B
folate	I-OUT	NOUN	B
values	I-OUT	NOUN	I
at	O	ADP	O
16-wk	O	ADJ	O
postpartum	O	NOUN	B
correctly	O	ADV	O
identified	O	VERB	B
the	O	DET	O
quartile	O	NOUN	B
of	O	ADP	O
folate	O	NOUN	B
intake	O	NOUN	B
of	O	ADP	O
only	O	ADV	O
26	O	NUM	O
of	O	ADP	O
55	O	NUM	O
(	O	PUNCT	O
47	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
18	O	NUM	O
of	O	ADP	O
55	O	NUM	O
(	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
subjects	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
treatment	O	NOUN	B
outcomes	B-OUT	NOUN	B
after	O	ADP	O
guided	B-I	VERB	B
tissue	I-I	NOUN	I
regeneration	I-I	NOUN	I
(	I-I	PUNCT	O
GTR	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
a	O	DET	O
bioabsorbable	O	ADJ	B
membrane	O	NOUN	I
in	O	ADP	O
Class	B-P	NOUN	B
II	I-P	NUM	I
furcation	I-P	NOUN	B
defects	I-P	NOUN	B
in	O	ADP	O
mandibular	O	ADJ	B
molars	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Nine	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
two	I-P	NUM	O
comparable	I-P	ADJ	O
Class	I-P	NOUN	B
II	I-P	NUM	I
furcation	I-P	NOUN	B
defects	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
radiographs	B-I	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
subtraction	O	NOUN	B
radiography	O	NOUN	I
.	O	PUNCT	O


GTR	B-I	NOUN	B
provided	O	VERB	O
complete	O	ADJ	O
closure	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
furcation	I-OUT	NOUN	B
defect	I-OUT	NOUN	O
in	O	ADP	O
two	O	NUM	O
sites	O	NOUN	B
and	O	CCONJ	O
superior	B-OUT	ADJ	B
horizontal	I-OUT	ADJ	B
clinical	I-OUT	ADJ	B
attachment	I-OUT	NOUN	O
level	I-OUT	NOUN	O
gain	I-OUT	NOUN	O
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
2.27	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.01	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
overall	O	ADJ	I
trend	O	NOUN	O
for	O	ADP	O
lower	O	ADJ	B
RU	B-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
sibenadet	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
correlates	O	VERB	O
with	O	ADP	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
sustained	O	ADJ	O
clinical	O	ADJ	B
effect	O	NOUN	I
seen	O	VERB	O
in	O	ADP	O
studies	O	NOUN	B
conducted	O	VERB	O
concurrently	O	ADV	O
.	O	PUNCT	O


Using	O	VERB	O
the	O	DET	O
belief	B-I	NOUN	B
basis	I-I	NOUN	O
of	I-I	ADP	O
the	I-I	DET	O
theory	I-I	NOUN	B
of	I-I	ADP	O
planned	I-I	VERB	B
behavior	I-I	NOUN	I
(	I-I	PUNCT	O
TPB	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
explored	O	VERB	O
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
mild	I-OUT	ADJ	B
reactions	I-OUT	NOUN	I
reported	O	VERB	O
by	O	ADP	O
donors	O	NOUN	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
their	O	PRON	O
first	O	ADJ	O
donation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
intention	O	NOUN	B
and	O	CCONJ	O
beliefs	O	NOUN	B
of	O	ADP	O
those	O	DET	O
donors	O	NOUN	B
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
returning	O	VERB	O
to	O	PART	O
donate	O	VERB	O
again	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
vascular	B-P	ADJ	B
femoral	I-P	ADJ	I
head	I-P	NOUN	I
necrosis	I-P	NOUN	I
is	I-P	AUX	O
a	I-P	DET	O
serious	I-P	ADJ	O
illness	I-P	NOUN	B
,	I-P	PUNCT	O
especially	I-P	ADV	O
when	I-P	SCONJ	O
appearing	I-P	VERB	O
in	I-P	ADP	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
30	I-P	NUM	O
to	I-P	PART	O
50	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
signal	O	NOUN	B
intensity	O	NOUN	I
by	O	ADP	O
the	O	DET	O
dynamic	B-OUT	ADJ	B
screening	I-OUT	NOUN	I
sequence	I-OUT	NOUN	I
is	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
an	O	DET	O
objective	O	ADJ	O
contribution	O	NOUN	B
for	O	ADP	O
the	O	DET	O
staging	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
femoral	I-OUT	ADJ	B
head	I-OUT	NOUN	I
necrosis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
enables	O	VERB	O
one	O	NUM	O
to	O	PART	O
differentiate	O	VERB	B
between	B-P	ADP	O
the	I-P	DET	O
curable	I-OUT	ADJ	B
stage	I-OUT	NOUN	B
IIc	I-OUT	NOUN	B
and	I-P	CCONJ	O
the	I-P	DET	O
stage	I-OUT	NOUN	B
III	I-OUT	NUM	I
,	I-P	PUNCT	O
showing	I-P	VERB	O
the	I-P	DET	O
beginning	I-P	NOUN	O
of	I-P	ADP	O
breakdown	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
femoral	I-OUT	ADJ	B
head	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Aminocaproic	B-I	ADJ	B
acid	I-I	NOUN	I
versus	O	CCONJ	O
prednisone	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
traumatic	B-P	ADJ	B
hyphema	I-P	NOUN	I
.	I-P	PUNCT	O


Blacks	B-P	NOUN	B
comprised	I-P	VERB	O
53	I-P	NUM	O
%	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
population	I-P	NOUN	I
,	I-P	PUNCT	O
and	I-P	CCONJ	O
the	I-P	DET	O
mean	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
patients	I-P	NOUN	B
was	I-P	AUX	O
23.5	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Sun	B-I	PROPN	O
protection	I-I	NOUN	B
behaviors	I-I	NOUN	O
and	O	CCONJ	O
stages	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
for	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
prevention	O	NOUN	I
of	O	ADP	O
skin	B-P	NOUN	B
cancers	I-P	NOUN	I
among	I-P	ADP	O
beachgoers	I-P	NOUN	B
in	I-P	ADP	O
southeastern	I-P	ADJ	B
New	I-P	PROPN	O
England	I-P	PROPN	O
.	I-P	PUNCT	O


We	O	PRON	O
report	O	VERB	O
characteristics	O	NOUN	B
of	O	ADP	O
a	O	DET	O
representative	B-P	ADJ	O
sample	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
2,324	I-P	NUM	O
)	I-P	PUNCT	O
of	I-P	ADP	O
beachgoers	I-P	NOUN	B
in	I-P	ADP	O
Southeastern	I-P	PROPN	B
New	I-P	PROPN	I
England	I-P	PROPN	I
during	I-P	ADP	O
the	I-P	DET	O
summer	I-P	NOUN	B
of	I-P	ADP	O
1995	I-P	NUM	O
.	I-P	PUNCT	O


Hyperbaric	B-I	NOUN	B
oxygen	I-I	NOUN	I
attenuation	O	NOUN	I
of	O	ADP	O
lipopolysaccharide-induced	B-P	ADJ	B
acute	I-P	ADJ	I
lung	I-P	NOUN	I
injury	I-P	NOUN	I
involves	O	VERB	O
heme	O	NOUN	B
oxygenase-1	O	NOUN	I
.	O	PUNCT	O


With	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
HBO	B-I	NOUN	B
pre-treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
rats	B-P	NOUN	B
were	O	AUX	O
further	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
the	O	DET	O
following	O	VERB	O
subgroups	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
:	O	PUNCT	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
LPS	B-I	NOUN	B
injection	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
ii	I-I	X	O
)	I-I	PUNCT	O
normal	I-I	ADJ	B
saline	I-I	NOUN	I
(	I-I	PUNCT	O
N/S	I-I	NOUN	B
)	I-I	PUNCT	O
injection	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
iii	I-I	X	O
)	I-I	PUNCT	O
hemin	I-I	NOUN	B
(	I-I	PUNCT	O
a	I-I	DET	O
HO-1	I-I	NOUN	B
inducer	I-I	NOUN	B
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
LPS	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
iv	I-I	X	O
)	I-I	PUNCT	O
hemin	I-I	NOUN	B
alone	I-I	ADV	O
,	I-I	PUNCT	O
(	I-I	PUNCT	O
v	I-I	X	O
)	I-I	PUNCT	O
tin	I-I	NOUN	O
protoporphyrin	I-I	NOUN	B
(	I-I	PUNCT	O
SnPP	I-I	NOUN	B
;	I-I	PUNCT	O
a	I-I	DET	O
HO-1	I-I	NOUN	B
inhibitor	I-I	NOUN	I
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
LPS	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
(	I-I	PUNCT	O
vi	I-I	X	O
)	I-I	PUNCT	O
SnPP	I-I	NOUN	B
alone	I-I	ADV	O
.	I-I	PUNCT	O


CONCLUSIONS	O	NOUN	O
HBO	B-I	PROPN	B
may	O	AUX	O
act	O	VERB	O
through	O	ADP	O
inhibiting	O	VERB	B
pulmonary	O	ADJ	B
iNOS	O	NOUN	B
expression	O	NOUN	B
to	O	PART	O
attenuate	O	VERB	B
LPS-induced	O	ADJ	B
acute	O	ADJ	O
lung	O	NOUN	O
injury	O	NOUN	O
in	O	ADP	O
septic	B-P	ADJ	B
rats	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
One-third	O	ADJ	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	B
population	O	NOUN	I
seems	O	VERB	O
to	O	PART	O
develop	O	VERB	O
minor	O	ADJ	O
recurrent	B-P	ADJ	O
aphthous	I-P	ADJ	O
stomatitis	I-P	NOUN	O
(	I-P	PUNCT	O
RAS	I-P	NOUN	B
)	I-P	PUNCT	O
during	O	ADP	O
their	O	PRON	O
lifetime	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
RAS	O	NOUN	B
decreased	O	VERB	B
with	O	ADP	O
perilla	B-I	NOUN	B
oil	I-I	NOUN	I
(	O	PUNCT	O
rich	O	ADJ	O
in	O	ADP	O
alpha-linolenic	O	ADJ	B
acid	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
samples	I-OUT	NOUN	I
were	O	AUX	O
collected	O	VERB	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
and	O	CCONJ	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
phase	O	NOUN	O
for	O	ADP	O
fatty	O	ADJ	B
acid	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
total	O	ADJ	O
plasma	O	NOUN	B
phospholipid	O	NOUN	O
fraction	O	NOUN	O
.	O	PUNCT	O


Occurrence	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
needed	I-OUT	VERB	O
days	I-OUT	NOUN	B
for	I-OUT	ADP	O
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
minor	I-OUT	ADJ	B
RAS	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
during	O	ADP	O
the	O	DET	O
two	O	NUM	O
phases	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
alpha-Linolenic	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
phospholipid	I-OUT	NOUN	O
fraction	I-OUT	NOUN	O
increased	I-OUT	VERB	B
significantly	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
during	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
phase	O	NOUN	O
to	O	PART	O
a	O	DET	O
similar	O	ADJ	O
extent	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
bone	B-P	NOUN	B
turnover	I-P	NOUN	B
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
therapy	O	NOUN	I
on	O	ADP	O
bone	O	NOUN	B
turnover	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Our	O	PRON	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
turnover	I-OUT	NOUN	B
and	O	CCONJ	O
bone	B-OUT	NOUN	B
mineral	I-OUT	ADJ	I
density	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
postmenopausal	B-P	ADJ	B
,	I-P	PUNCT	O
osteopenic	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Women	B-P	NOUN	B
aged	I-P	ADJ	B
50	I-P	NUM	O
to	I-P	PART	O
80	I-P	NUM	O
years	I-P	NOUN	B
received	O	VERB	O
raloxifene	B-I	NOUN	B
for	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
continue	O	VERB	O
raloxifene	B-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
1	I-P	NUM	O
,	I-P	PUNCT	O
n=20	I-P	ADJ	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
2	I-P	NUM	O
,	I-P	PUNCT	O
n=20	I-P	ADJ	O
)	I-P	PUNCT	O
for	I-P	ADP	O
a	I-P	DET	O
further	I-P	ADJ	O
96	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


Continuation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
maintained	O	VERB	B
these	O	DET	O
changes	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
bone	B-OUT	NOUN	B
markers	I-OUT	NOUN	B
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
levels	O	NOUN	B
(	O	PUNCT	O
by	O	ADP	O
120	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Hip	B-OUT	NOUN	B
BMD	I-OUT	PROPN	I
was	O	AUX	O
decreased	O	VERB	B
by	O	ADP	O
2	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
192	O	NUM	O
weeks	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
.	O	PUNCT	O


Bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
therapy	O	NOUN	I
at	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
accelerated	B-P	VERB	B
bone	I-P	NOUN	B
loss	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
turnover	I-OUT	NOUN	B
of	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
raloxifene	O	NOUN	B
was	O	AUX	O
lost	O	VERB	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
hydraulic	O	ADJ	B
circuit	O	NOUN	I
training	O	NOUN	O
on	O	ADP	O
cardiovascular	B-P	ADJ	B
function	I-P	NOUN	I
.	I-P	PUNCT	O


Maximal	B-OUT	ADJ	B
aerobic	I-OUT	ADJ	I
power	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VO2max	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
with	I-OUT	ADP	O
simultaneous	I-OUT	ADJ	B
measurement	I-OUT	NOUN	B
of	I-OUT	ADP	O
stroke	I-OUT	NOUN	B
volume	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
SV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cardiac	I-OUT	ADJ	B
output	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CO	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
by	I-OUT	ADP	O
impedance	I-OUT	ADJ	B
cardiography	I-OUT	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
assessed	O	VERB	B
pre-	O	ADJ	B
and	O	CCONJ	O
post-training	O	ADJ	B
.	O	PUNCT	O


Following	O	VERB	O
training	O	NOUN	B
VO2max	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
ml.kg-1	I-OUT	NOUN	B
min-1	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
all	O	DET	O
training	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
18.0	O	NUM	O
,	O	PUNCT	O
12.5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
11.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
cycle	O	NOUN	B
,	O	PUNCT	O
HCTsub	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
HCTmax	B-OUT	NOUN	B
groups	I-OUT	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


HR	B-OUT	NOUN	B
changes	O	NOUN	B
from	O	ADP	O
Baseline	O	NOUN	B
to	O	ADP	O
Heel	O	PROPN	B
Stick	O	PROPN	I
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
KC30	O	NOUN	B
and	O	CCONJ	O
KC15	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
IC	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
more	O	ADJ	O
infants	O	NOUN	B
had	O	AUX	O
HR	B-OUT	NOUN	B
decrease	O	NOUN	B
in	O	ADP	O
IC	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
2	O	NUM	O
KC	O	NOUN	B
conditions	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
3	O	NUM	O
conditions	O	NOUN	B
,	O	PUNCT	O
LF/HF	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
decreased	O	VERB	B
from	O	ADP	O
Baseline	O	NOUN	B
to	O	ADP	O
Heel	O	PROPN	B
Stick	O	PROPN	I
and	O	CCONJ	O
increased	O	VERB	B
to	O	ADP	O
Recovery	O	PROPN	B
;	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
IC	B-I	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
KC	B-I	NOUN	B
conditions	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
longer	O	ADV	B
and	O	CCONJ	O
shorter	O	ADJ	B
KC	B-I	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
throughout	O	ADP	O
heel	O	NOUN	B
stick	O	NOUN	I
can	O	AUX	O
stabilize	O	VERB	O
HR	B-OUT	NOUN	B
response	I-OUT	NOUN	B
in	O	ADP	O
preterm	O	NOUN	B
infants	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
longer	O	ADV	O
KC	B-I	PROPN	B
significantly	O	ADV	O
affected	O	VERB	B
infants	O	NOUN	B
'	O	PART	O
sympathetic	O	ADJ	B
and	O	CCONJ	O
parasympathetic	O	ADJ	B
responses	O	NOUN	I
during	O	ADP	O
heel	O	NOUN	B
stick	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
incubator	B-I	NOUN	B
care	I-I	NOUN	I
.	I-I	PUNCT	O


In	B-P	ADP	O
2003	I-P	NUM	O
50	I-P	NUM	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
one	I-I	NUM	O
or	I-I	CCONJ	O
two	I-I	NUM	O
epidural	I-I	ADJ	B
injections	I-I	NOUN	I
have	I-P	AUX	O
been	I-P	AUX	O
selected	I-P	VERB	O
"	I-P	PUNCT	O
ad	I-P	NOUN	B
random	I-P	ADJ	I
"	I-P	PUNCT	O
and	I-P	CCONJ	O
50	I-P	NUM	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
disc	I-I	NOUN	B
coablation	I-I	NOUN	I
.	I-I	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
average	B-OUT	ADJ	B
VAS	I-OUT	NOUN	B
was	O	AUX	O
clearly	O	ADV	O
lower	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
coablation	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
epidural	B-I	ADJ	B
injections	I-I	NOUN	I
.	O	PUNCT	O


51	B-P	NUM	O
patients	I-P	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
one	O	NUM	O
in	O	ADP	O
acupuncture	B-I	NOUN	B
treatment	I-I	NOUN	I
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
without	O	ADP	O
any	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	O
revealed	O	VERB	B
that	O	SCONJ	O
acupuncture	B-I	NOUN	B
seemed	O	VERB	O
to	O	PART	O
have	O	AUX	O
more	O	ADV	O
affect	O	VERB	O
on	O	ADP	O
OKT4+	B-OUT	ADJ	B
cells	I-OUT	NOUN	I
than	O	ADP	O
on	O	ADP	O
OKT8+	B-OUT	ADJ	B
cells	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


RESULTS	O	NOUN	B
PECS	B-OUT	NOUN	B
was	I-OUT	AUX	O
more	I-OUT	ADV	O
successful	I-OUT	ADJ	O
than	I-OUT	ADP	O
RPMT	I-OUT	NOUN	B
in	I-OUT	ADP	O
increasing	I-OUT	VERB	B
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
nonimitative	I-OUT	ADJ	B
spoken	I-OUT	VERB	B
communication	I-OUT	NOUN	B
acts	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
different	I-OUT	ADJ	O
nonimitative	I-OUT	ADJ	B
words	I-OUT	NOUN	B
used	I-OUT	VERB	O
at	I-OUT	ADP	O
the	I-OUT	DET	O
posttreatment	I-OUT	NOUN	B
period	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
analogous	B-OUT	ADJ	O
slopes	I-OUT	NOUN	B
were	O	AUX	O
steeper	O	ADJ	O
in	O	ADP	O
the	O	DET	O
RPMT	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
PECS	O	NOUN	B
group	O	NOUN	B
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
began	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
relatively	O	ADV	O
low	O	ADJ	B
object	O	NOUN	B
exploration	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
cavities	B-P	NOUN	B
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
adhesive	O	ADJ	B
system	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
restored	O	VERB	B
with	O	ADP	O
flowable	O	ADJ	B
composite	O	NOUN	I
according	O	VERB	O
to	O	ADP	O
manufacturer	O	NOUN	B
's	O	PART	I
instructions	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
noted	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
enamel	B-I	NOUN	B
preparation	I-I	NOUN	O
when	O	SCONJ	O
etching	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Preparing	O	VERB	B
and	O	CCONJ	O
treating	O	VERB	B
the	O	DET	O
enamel	O	NOUN	B
surface	O	NOUN	B
exclusively	O	ADV	O
by	O	ADP	O
Er	B-I	NOUN	B
:	I-I	PUNCT	O
YAG	I-I	NOUN	B
laser	I-I	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
degree	B-OUT	NOUN	B
of	I-OUT	ADP	O
leakage	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Dexmedetomidine	B-I	NOUN	B
pretreatment	O	NOUN	B
alleviates	O	VERB	O
propofol	B-P	NOUN	B
injection	I-P	NOUN	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
propofol	B-I	NOUN	B
injection	O	NOUN	B
pain	O	NOUN	I
during	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
varies	O	VERB	O
from	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
to	O	PART	O
90	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Experimental	O	ADJ	B
treatments	O	NOUN	I
were	O	AUX	O
intravenously	O	ADV	B
administered	O	VERB	B
over	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
(	O	PUNCT	O
total	O	ADJ	B
volume	O	NOUN	I
10	O	NUM	O
mL	O	NOUN	O
)	O	PUNCT	O
prior	O	ADJ	O
to	O	PART	O
intravenous	O	ADJ	B
propofol	B-I	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
isotonic	B-I	ADJ	B
saline	I-I	NOUN	I
.	I-I	PUNCT	O


The	B-OUT	DET	O
median	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
score	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
>	O	VERB	O
2	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
VII	O	NOUN	B
were	O	AUX	O
both	O	CCONJ	O
significantly	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.000	O	NUM	O
,	O	PUNCT	O
both	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
persistent	I-P	ADJ	B
AF	I-P	NOUN	I
or	I-P	CCONJ	O
AF	I-P	NOUN	B
induced	I-P	VERB	B
during	I-P	ADP	O
a	I-P	DET	O
routine	I-P	ADJ	B
electrophysiology	I-P	NOUN	B
study	I-P	NOUN	I
(	I-P	PUNCT	O
EPS	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
low-tilt	B-I	ADJ	B
waveform	I-I	NOUN	I
or	O	CCONJ	O
a	O	DET	O
conventional	B-I	ADJ	B
waveform	I-I	NOUN	I
.	I-I	PUNCT	O


Plasmakinetic	B-I	ADJ	B
prostate	I-I	NOUN	I
resection	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
benign	O	ADJ	B
prostate	O	NOUN	O
hyperplasia	O	NOUN	O
:	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
1-year	O	ADJ	O
follow	O	NOUN	B
up	O	ADP	I
.	O	PUNCT	O


The	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
Na	I-OUT	NOUN	B
level	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
TURP	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Differential	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
resistance	B-I	NOUN	B
training	I-I	NOUN	O
in	O	ADP	O
CHF	O	NOUN	B
according	O	VERB	O
to	O	PART	O
ACE	O	NOUN	B
genotype	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
ACE	O	NOUN	B
genotype	O	NOUN	B
on	O	ADP	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
moderate	O	ADJ	B
intensity	O	NOUN	O
circuit	O	NOUN	O
resistance	B-I	NOUN	O
training	I-I	NOUN	O
in	O	ADP	O
chronic	B-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
(	I-P	PUNCT	O
CHF	I-P	NOUN	B
)	I-P	PUNCT	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
ACE	O	NOUN	B
genotype	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
response	O	NOUN	B
to	O	ADP	O
11weeks	B-I	NOUN	O
of	I-I	ADP	O
resistance	I-I	NOUN	B
exercise	I-I	NOUN	B
training	I-I	NOUN	O
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
37	B-P	NUM	O
CHF	I-P	NOUN	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
New	I-P	PROPN	B
York	I-P	PROPN	I
Heart	I-P	PROPN	I
Association	I-P	PROPN	I
Functional	I-P	ADJ	O
Class=2.3±0.5	I-P	NOUN	O
;	I-P	PUNCT	O
left	I-P	VERB	B
ventricular	I-P	ADJ	I
ejection	I-P	NOUN	I
fraction	I-P	NOUN	I
28±7	I-P	NUM	O
%	I-P	NOUN	O
;	I-P	PUNCT	O
age	I-P	NOUN	B
64±12years	I-P	NOUN	O
;	I-P	PUNCT	O
32:5	I-P	NOUN	O
male	I-P	NOUN	B
:	I-P	PUNCT	O
female	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
randomised	I-P	VERB	B
to	O	PART	O
either	B-I	CCONJ	O
resistance	I-I	NOUN	B
exercise	I-I	NOUN	B
(	O	PUNCT	O
n=19	O	ADJ	O
)	O	PUNCT	O
or	B-I	CCONJ	O
inactive	I-I	ADJ	B
control	I-I	NOUN	O
group	I-I	NOUN	O
(	O	PUNCT	O
n=18	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Outcome	O	NOUN	B
measures	O	NOUN	I
included	B-OUT	VERB	O
V˙O	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2peak	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
peak	I-OUT	ADJ	B
power	I-OUT	NOUN	I
output	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
muscle	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
endurance	I-OUT	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
I	O	NOUN	B
allele	O	NOUN	B
had	O	AUX	O
higher	B-OUT	ADJ	O
V˙O	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2peak	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
p=0.02	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
peak	I-OUT	VERB	B
power	I-OUT	NOUN	I
(	O	PUNCT	O
p=0.003	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	O
to	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
D	O	NOUN	B
allele	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
genotype-dependent	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
observed	B-OUT	VERB	O
in	I-OUT	ADP	O
V˙O	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2peak	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
muscle	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
muscle	I-OUT	NOUN	B
endurance	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
lactate	I-OUT	NOUN	B
threshold	I-OUT	NOUN	I
.	O	PUNCT	O


Many	O	ADJ	O
athletes	B-P	NOUN	B
arrive	O	VERB	O
at	O	ADP	O
training	O	NOUN	B
sessions	O	NOUN	B
and	O	CCONJ	O
competitions	O	NOUN	B
in	O	ADP	O
a	O	DET	O
mildly	B-P	ADV	B
hypohydrated	I-P	VERB	O
(	I-P	PUNCT	O
HYPO	I-P	NOUN	B
)	I-P	PUNCT	O
state	I-P	NOUN	O
and	O	CCONJ	O
are	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
drink	O	VERB	B
fluids	O	NOUN	I
before	O	ADP	O
exercise	O	NOUN	B
to	O	PART	O
reach	O	VERB	O
a	O	DET	O
euhydrated	O	ADJ	B
(	O	PUNCT	O
HYD	O	NOUN	B
)	O	PUNCT	O
state	O	NOUN	O
.	O	PUNCT	O


Ten	B-P	NUM	O
recreational	I-P	ADJ	B
athletes	I-P	NOUN	B
(	I-P	PUNCT	O
6	I-P	NUM	O
women	I-P	NOUN	B
,	I-P	PUNCT	O
4	I-P	NUM	O
men	I-P	NOUN	B
;	I-P	PUNCT	O
71.9	I-P	NUM	O
±	I-P	NOUN	O
4.6	I-P	NUM	O
kg	I-P	NOUN	O
,	I-P	PUNCT	O
25.2	I-P	NUM	O
±	I-P	NOUN	O
0.9	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
participated	I-P	VERB	O
in	O	ADP	O
the	O	DET	O
studies	O	NOUN	B
to	O	PART	O
examine	O	VERB	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
the	O	DET	O
day-to-day	O	NOUN	B
variability	O	NOUN	B
of	O	ADP	O
morning	O	NOUN	B
urine	O	NOUN	B
specific	O	ADJ	O
gravity	O	NOUN	O
(	O	PUNCT	O
USG	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
consuming	B-I	VERB	O
600	I-I	NUM	O
ml	I-I	NOUN	O
of	I-I	ADP	O
water	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
hydration	O	NOUN	B
status	O	NOUN	B
of	O	ADP	O
HYD	O	NOUN	B
and	O	CCONJ	O
HYPO	O	NOUN	B
(	O	PUNCT	O
USG	O	NOUN	B
>	O	X	O
1.020	O	NUM	O
)	O	PUNCT	O
subjects	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
c	O	X	O
)	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
consuming	B-I	VERB	B
water	I-I	NOUN	I
(	I-I	PUNCT	O
W	I-I	NOUN	O
)	I-I	PUNCT	O
,	I-I	PUNCT	O
salt-water	I-I	NOUN	B
(	O	PUNCT	O
SW	O	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
mM	O	NOUN	O
Na	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	B-I	DET	O
carbohydrate-electrolyte	I-I	ADJ	B
solution	I-I	NOUN	O
with	I-I	ADP	O
3	I-I	NUM	O
%	I-I	NOUN	O
or	I-I	CCONJ	O
light	I-I	ADJ	B
carbohydrate	I-I	NOUN	I
(	O	PUNCT	O
CES-L	O	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
mM	O	NOUN	O
Na	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
a	B-I	DET	O
CES	I-I	PROPN	B
with	I-I	ADP	O
6	I-I	NUM	O
%	I-I	NOUN	O
carbohydrate	I-I	NOUN	B
(	O	PUNCT	O
CES	O	PROPN	B
,	O	PUNCT	O
20	O	NUM	O
mM	O	NOUN	O
Na	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
hydration	O	NOUN	B
status	O	NOUN	B
of	O	ADP	O
HYPO	O	NOUN	B
subjects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
day-to-day	O	ADJ	B
variability	O	NOUN	B
in	O	ADP	O
morning	O	NOUN	B
USG	O	PROPN	B
(	O	PUNCT	O
coefficient	O	NOUN	B
of	O	ADP	I
variation	O	NOUN	I
=	O	ADJ	O
0.2	O	NUM	O
±	O	NOUN	O
0.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
low	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
responses	O	NOUN	B
to	O	PART	O
600	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
W	O	NOUN	O
ingestion	O	NOUN	B
were	O	AUX	O
repeatable	B-OUT	ADJ	O
.	I-OUT	PUNCT	O


In	O	ADP	O
the	O	DET	O
CES	O	PROPN	B
study	O	NOUN	B
,	O	PUNCT	O
HYPO	O	NOUN	B
subjects	O	NOUN	B
reached	O	VERB	O
HYD	O	NOUN	B
status	O	NOUN	B
at	O	ADP	O
45	O	NUM	O
minutes	O	NOUN	B
in	O	ADP	O
all	O	DET	O
conditions	O	NOUN	B
(	O	PUNCT	O
W	O	NOUN	O
1.013	O	NUM	O
±	O	NOUN	O
0.003	O	NUM	O
,	O	PUNCT	O
SW	O	NOUN	B
1.013	O	NUM	O
±	O	NOUN	O
0.003	O	NUM	O
,	O	PUNCT	O
CES-L	O	NOUN	B
1.011	O	NUM	O
±	O	NOUN	O
0.003	O	NUM	O
,	O	PUNCT	O
CES	O	PROPN	B
1.017	O	NUM	O
±	O	NOUN	O
0.004	O	NUM	O
)	O	PUNCT	O
because	O	SCONJ	O
salt	O	NOUN	B
or	O	CCONJ	O
CES	O	ADJ	B
ingestion	O	NOUN	B
did	O	AUX	O
not	B-OUT	PART	O
affect	I-OUT	VERB	O
fluid	I-OUT	ADJ	B
retention	I-OUT	NOUN	O
(	O	PUNCT	O
W	O	NOUN	O
68	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
SW	O	NOUN	B
72	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
CES-L	O	NOUN	B
68	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
CES	O	PROPN	B
76	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Following	O	VERB	O
baseline	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
patients	O	NOUN	B
entered	O	VERB	O
a	O	DET	O
19-week	O	ADJ	O
double-blind	O	ADJ	B
phase	B-I	NOUN	O
:	I-I	PUNCT	O
6-week	I-I	ADJ	B
titration	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
mg/week	I-I	NOUN	B
increments	I-I	NOUN	B
to	I-I	PART	O
target	I-I	VERB	B
dose	I-I	NOUN	B
)	I-I	PUNCT	O
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
13-week	I-I	NOUN	O
maintenance	I-I	NOUN	B
period	I-I	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
intent-to-treat	O	ADJ	B
population	O	NOUN	I
over	O	ADP	O
the	O	DET	O
double-blind	O	ADJ	B
phase	O	NOUN	B
,	O	PUNCT	O
the	B-OUT	DET	O
median	I-OUT	ADJ	B
percent	I-OUT	NOUN	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
seizure	I-OUT	NOUN	B
frequency	I-OUT	NOUN	B
was	O	AUX	O
-21.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
-26.3	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
-34.5	O	NUM	O
%	O	NOUN	O
for	B-I	ADP	O
placebo	I-I	NOUN	B
and	I-I	CCONJ	O
perampanel	I-I	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0261	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.0158	O	NUM	O
for	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
vs	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Fifty	O	NUM	O
percent	O	ADJ	O
responder	O	NOUN	B
rates	O	NOUN	B
during	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
period	O	NOUN	B
were	O	AUX	O
26.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
37.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
36.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
for	B-I	ADP	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
perampanel	I-I	NOUN	B
8	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
and	B-I	CCONJ	O
perampanel	I-I	NOUN	B
12	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
for	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0760	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0914	B-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O
